Risk factors for paravalvular leak after transcatheter aortic valve implantation

Krzysztof Wilczek1, Kamil Bujak2, Rafał Reguła2, Piotr Chodór3, Tadeusz Osadnik1

13rd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland
2Medical University of Silesia, Katowice, Poland
3Chair of Cardiology, Congenital Heart Diseases, and Electrotherapy, Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland

Kardiochirurgia i Torakochirurgia Polska 2015; 12 (2): 89-94

DOI: 10.5114/kitp.2015.52848

Introduction

The method of transcatheter aortic valve implantation (TAVI) introduced in 2002 by Alain Cribier et al. has offered new prospects for patients with severe aortic stenosis and multiple comorbidities, for whom surgical procedures are associated with exceedingly high operative risk [1, 2]. The randomized multicenter PARTNER trial (Placement of AoRtic TraNs catheterER Valve Trial) proved that TAVI is an alternative for surgical aortic valve replacement (SAVR) for high-risk patients; it is characterized by similar mortality and results in terms of reducing the symptoms of stenosis, but it is associated with a higher incidence of paravalvular leak (PVL) [3].

The presence of aortic regurgitation (AR) jet from the aorta into the left ventricle is the most common complication after TAVI, occurring in as many as 70% of patients; notwithstanding, its grade is usually trivial or mild [4, 5]. In most previous studies, mild AR was not associated with significantly shorter survival time [4, 5]; however, the PARTNER trial demonstrated that it may be associated with worse long-term prognosis [3]. Significant AR (moderate and severe) is less common, occurring in approximately 15-20% of cases [6], and is one of the most important prognostic factors of mortality during short- and long-term follow-up [7, 8]. It is, therefore, essential to understand the mechanisms and risk factors associated with the occurrence of AR in order to minimize its incidence.

Most cases of AR after TAVI are associated with PVL. Transvalvular regurgitation (TVR) occurs much less frequently and is sometimes concomitant with PVL [8-10]. Some authors do not distinguish between these two types of regurgitation. Nonetheless, the mechanisms specific for the development of TVR will not be the subject of this paper since significant TVR is a much less frequent complication whose pathophysiological mechanism is different from that of PVL.

Paravalvular leaks are characterized by complex etiology, but in most cases the mechanism of leak development is associated with insufficient contact of the prosthesis to the aortic annulus, prosthesis-patient mismatch, or malap-
position of the prosthesis. The risk factors for PVL after TAVI can therefore be divided into anatomical factors, factors associated with the clinical characteristics of the patient (patient-dependent factors), and factors associated with the procedure itself (procedure- and operator-dependent factors) [11].

Anatomical and clinical factors

The anatomy of the aortic annulus, which is the device landing zone (DLZ) for both self-expanding and balloon-expandable aortic valve prostheses, plays an important role in the etiopathogenesis of PVL [7, 12]. In contrast to SAVR, it is impossible to directly evaluate the size and shape of the annulus during TAVI. Therefore it is necessary to employ imaging techniques such as transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), multirow-detector computed tomography (MDCT), aortography, or magnetic resonance [13]. In current clinical practice, two-dimensional TEE is the method most commonly used for annular assessment, but this technique has numerous limitations [5, 14]. Like TTE, TEE enables to evaluate only one dimension of the annulus, which does not always reveal the maximum annular diameter. This may lead to underestimation in contrast to MDCT, which enables three-dimensional (planimetric) evaluation [9, 15-17]. This stems from the fact that presenting the aortic annulus as a circle is a crude approximation. Tops et al. reported that in 47% of the studied patients the aortic annulus was oval in shape; i.e., its diameter in the frontal plane was at least 3 mm larger than in the sagittal plane [15]. Planimetric evaluation provides the ability to establish both the longest and shortest diameter, as well as the diameter calculated based on annular circumference or area; thus, it provides more precise information in the case of elliptical aortic annuli. Furthermore, MDCT provides additional information about other anatomical risk factors for PVL occurrence, such as the mass and distribution of calcifications, which confirms the validity of using this imaging method in the evaluation of native valve anatomy [15, 18, 19].

Shape and size of the aortic annulus

The most often used measure of aortic annulus ovality is the annulus eccentricity index (AEI) defined as $1 - \frac{(\text{the quotient of the shortest and longest diameter of the aortic annulus})}{2}$. Based on this formula, AEI is equal to 0 for a perfect circle and increases with the rise of annulus ovality [20]. Wong et al. demonstrated that AEI correlates strongly with the occurrence of significant paravalvular leaks after the implantation of CoreValve (CV) devices and that, for the assumed AEI cut-off point of $> 0.25$, it enables to predict PVL occurrence with 80% sensitivity and 86% specificity [22]. These findings were confirmed by Hahn et al. who proved that AEI correlates with the PVL grade [23]. However, not all reports on the association between PVL and the oval shape of the annulus are consistent. Marwan et al. [24] and Hanson et al. [21] did not confirm the association between AEI and the grade of PVL in groups of patients who were treated with balloon-expandable Edwards-Sapien (ES) valves. The different results may have been related to the used valve type. Balloon-expandable prostheses, characterized by substantial stiffness, retain their circular shape regardless of the anatomy of the aortic annulus [25], stretching the annulus, which is associated with the increase of the shorter annulus diameter and the reduction of the longer one, in effect leading to a significant reduction of AEI after valve implantation [9].

Another well-known risk factor for PVL is the aortic annulus diameter. Risk for PVL rises with increased annulus diameter [13, 26]. This probably explains more frequent occurrence of significant leaks in patients with a large body surface area [23], tall persons [7, 27], and men [5, 23, 27]. The relationship between the size of the annulus and PVL development can most likely be explained by the limited spectrum of valve sizes and the difficulties with selecting adequate valves for patients with larger aortic annuli [27]. Recently, Masri et al. used a novel method of evaluating the change of annular shape during the whole cardiac cycle using MDCT with software enabling four-dimensional imaging (three-dimensional projections analyzed over time). They demonstrated that a small difference between the largest and smallest diameter of the annulus evaluated during the whole cardiac cycle (low annulus deformability) significantly predisposes to PVL and TVR after TAVI procedures [28].

LVOT-ascending aorta angle

Sherif et al. conducted a study in a group of patients undergoing CV implantation and found a relationship between the occurrence of significant PVL after TAVI and the angle between the left ventricular outflow tract (LVOT) and the first 4 cm of the ascending aorta (AO) [29]. The angle was an independent risk factor for PVL: the risk increased with the rise of the angle width (OR = 1.24). CV device, implanted into the left ventricular outflow tract and reaching into the ascending aorta in patients with large LVOT-AO angles, is exposed to significant tension, which may lead to stent deformation, causing a reduction in the tightness of the paravalvular space [12]. To the best of our knowledge, no study has confirmed the influence of large LVOT-AO angles on the development of AR in patients with ES valves. The design of the latter one is different, and the valves are implanted almost exclusively at the level of the aortic annulus.

Extent and distribution of calcifications

The presence of calcifications on the degenerated native valve is very common in patients with aortic stenosis. It is associated with stenosis progression and occurs, to varied extent, in practically all patients with severe aortic stenosis [15, 30, 31]. It is widely believed that the presence of extensive calcifications in the DLZ precludes complete prosthetic expansion and its precise apposition to the native valve and LVOT, thus favoring the development of PVL. This hypothesis was confirmed by the results of most studies. Delgado et al. evaluated the total amount of calci-
The data concerning the influence of calcifications asymmetry and their location in specific DLZ points on the development of PVL are more ambiguous than in the case of the total amount of calcium. Ewe et al. discovered that PVL location using echocardiography after TAVI depends on the location of the calcifications; i.e., a PVL is most likely to occur if there is a large volume of calcium at the wall of valve cusp, while the risk is lower if the calcifications are located on the free cusp margins or within the valve cusps. The situation is similar in the case of PVL at the cusps commissures, which is most often associated with calcifications located on the commissures and, to a lesser extent, with the presence of calcification on the free margins of the valve cusps [18]. Other factors related to PVL development included the asymmetric distribution of calcifications [10] as well as the presence of calcifications on individual cusp commissures [19, 33] and within the valve cusps [33]. Some of the studies did not confirm the existence of a relationship between the location and asymmetric distribution of calcifications and the occurrence of PVL and TVR [32, 35, 36]. Substantial differences in the results of the mentioned studies may stem from the use of various methods of evaluating calcification (MDCT, echocardiography), the assumption of various definitions for calcification distribution and asymmetry, as well as relatively small patient groups.

Other anatomical and clinical risk factors for the leak

Apart from the risk factors mentioned above and analyzed by numerous studies, there are a number of factors related to the anatomical and clinical characteristics of patients that have been analyzed by fewer researchers. These factors include the aortic valve area (the larger the area, the smaller the risk of AR) [5, 37], high baseline transvalvular gradient [38], ejection fraction < 30% [5], symptomatic heart failure in NYHA class IV [10], peripheral vascular disease [26], and other factors for which it is difficult to unequivocally explain their relationship with the etiology of the leak, e.g., renal failure [5]. In turn, leak development has not been shown to be influenced by the size of the sinus of Valsalva or the ascending aorta, i.e., structures belonging to the DLZ that could potentially constitute factors influencing AR [22, 29].

A separate issue is bicuspid aortic valve (BAV), which is a relative contraindication for TAVI [39] even though it occurs relatively often (in about 20% of cases) in the group of patients who are potential candidates for this treatment [39]. Bicuspid valves are more oval in shape, have larger annuli, and are characterized by massive and asymmetric calcifications; therefore they have many features that have been demonstrated to predispose to leak development [40]. Furthermore, the study by Abdel-Wahab et al. demonstrated a trend of more frequent AR occurrence in patients with BAV [5]. On the other hand, the most recent studies have shown that AR was not more common in selected BAV patients than in patients with tricuspid valves [41, 42]. However, these data come from relatively small registers, so they do not constitute sufficient evidence for using TAVI routinely in the group of patients with BAV.

Procedural factors

Apart from factors associated with the anatomy and clinical characteristics of the patient, factors associated with procedure also play an important role in leak development. They include, among others, the selection of an appropriate imaging modality for the evaluation of key anatomical parameters of the DLZ as well as the selection of valve type and size. The experience of the center and operators also plays a significant role. Procedural risk factors are especially important for clinicians, because they can potentially be modified in order to limit the occurrence of PVL after TAVI and improve treatment outcomes.

Valve type

The occurrence of PVL may be influenced by the selection of the valve type. In some studies, patients received CV prostheses suffered from significant AR more frequently than patients who received ES valves [37, 43]. Different results were provided by a large British registry encompassing 2584 patients, indicating that the use of balloon-expandable prostheses increases the risk of significant PVL. Moreover, an interesting conclusion of the study was that the postoperative presence of moderate/severe AR had a significant influence on mortality only in the group of patients treated with balloon-expandable valves and not in all patients undergoing TAVI [38]. To the best of our knowledge, there are no other studies confirming this relationship. The introduction to the market of new generations of repositionable valves whose structure increases the tightness between the annulus and the prosthesis raises hopes for reducing the incidence of PVL after TAVI. Especially promising are the outcomes of clinical studies concerning the Lotus valve (Boston Scientific, Marlborough, Massachu-
sets, USA) and the Direct Flow Medical valve (Direct Flow Medical Inc., Santa Rosa, CA, USA). The published results of the clinical REPRISE II study investigating Lotus device, demonstrated that moderate PVL was present in only 1% of patients 30 days after the procedure; in the remaining cases there was no leak or the leak was mild, whereas in study investigating Direct Flow Medical valve only one case of moderate PVL in a group of 74 patients occurred [44, 45]. Perhaps, if the new generation valves enable a significant reduction of PVL occurrence, it will be possible to extend the indications for TAVI to patients with lower surgical risk.

**Valve size selection and imaging**

The selection of the appropriate size of the prosthesis in relation to the aortic annulus size is one of the key elements of preparing for TAVI procedures. Too small valve prevents the prosthesis from adhering tightly to the annulus, which results from the insufficient transverse force exerted on the aortic valve complex by the prosthesis; thus, it may lead to lack of tightness around the prosthesis and, consequently, to PVL [7, 46]. In turn, implanting a valve that is too large may cause such complications as annulus rupture or coronary artery occlusion [7, 9]; notwithstanding, in order to minimize the risk of PVL, the use of valves that are slightly oversized is recommended [47]. One of the most important risk factors for PVL is the cover index (CI), which depends on the size of the prosthetic valve and the aortic annulus and is defined by the following formula: [100 × (external diameter of the prosthetic valve – aortic annulus diameter)/ external diameter of the prosthetic valve] – the lower the CI value, the higher the risk [7, 20]. Détain et al. observed that, in their group of patients with balloon-expandable valves, significant PVL never occurred when CI was > 8% [7].

The proper annulus evaluation plays the key role in the selection of valve size. As mentioned above, the annulus diameter established on the basis of two-dimensional TEE may be underestimated. To the best of our knowledge, there have been no randomized studies comparing the incidence of PVL in patients whose aortic annuli were assessed with two-dimensional TEE and MDCT. A retrospective study by Mylotte et al. demonstrated that 50% of patients would have been provided with CV valves of inadequate size (inconsistent with current recommendations) if the selection had been based on the annulus size established by TEE examination. Moreover, the authors reported that the selection of the recommended valve size based on MDCT measurements enables to achieve a 20% reduction of the incidence of significant PVL [46].

The incidence of this complication can also be minimized by using the optimal (coplanar) fluoroscopy projections, which facilitates proper valve positioning and implantation [48].

**Other procedural risk factors for PVL**

The depth of implantation appears to be a predictive factor for PVL that is characteristic of the CV device. In contrast to the ES valve, which can only be implanted in a narrow range of depths, the CV device has high profile and that can be placed at a wider range of depths [29]. However, if the valve is implanted too deep (low), this can result in a leak through the stent cells, as its structure is covered with porcine pericardium only in the lower part of the prosthesis [49]. Sherif et al. established that the optimal implantation was performed when depth of the device in relation to the noncoronary cusp was ∼10 mm.

Implanting the valve in a lower or higher position was associated with higher grade of AR [29]. In turn, in a study by Takagi et al., low valve implantation (≥ 3 stent cells below the valve annulus) was an independent risk factor for significant PVL (OR = 3.67) [26].

The experience of the center and operator performing TAVI also affects the outcome. The influence of the learning curve on AR incidence has been clearly demonstrated; the incidence is failing with growing number of performed procedures [7, 50].

**Conclusion**

Paravalvular leak is currently one of the most significant problems connected with TAVI procedures. There are many factors known to predict the occurrence of this complication. Understanding these factors may improve the assessment of risk and the selection of more personalized treatment. The increasing number of TAVI performed around the world, the optimization of procedures based on data from large clinical studies, and the introduction of new technologies associated with prosthetic valves and imaging methods offer a chance for a substantial reduction in the incidence of significant PVL, thus improving the prognosis of patients undergoing TAVI.

**Disclosure**

Authors report no conflict of interest.

**References**

1. Criber A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation 2002; 106: 3006-3008.
2. Wilczek K, Chodór P, Zembala M. Transcatheter aortic valve implantation – time to start in Poland. Kardiol Pol 2008; 66: 1144-1152.
3. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Sesto WF, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-1695.
4. Tamburino C, Capodanno D, Ramondo A, Petronio A, Ettori F, Santoro G, Klugmann S, Bedogni F, Maisano F, Marzocchi A, Pili A, Antonucci D, Napodano M, De Carlo M, Fiorina C, Ussia GP. Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis. Circulation 2011; 123: 299-308.
5. Abdel-Wahab M, Zahn R, Horack M, Gerckens U, Schuler G, Sievert H, Eggbrecht H, Senges J, Richardt G. Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registry. Heart 2011; 97: 899-906.
21. Hansson NC, Thuesen L, Hjortdal VE, Leipsic J, Andersen HR, Poulsen SH, Andersen WN, Wang D, Pocock S. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med 2010; 363: 1597-1607.

22. Willson AB, Webb JG, Laboaty TM, Achenbach S, Moss R, Wheeler M, Thompson C, Min JK, Gurvitch N, Norgaard BL, Hague CJ, Togweiler S, Binder R, Freeman M, Poultier R, Poulsens S, Wood DA, Leipsic J. 1-dimen-

sional aortic annular assessment by multidetector computed tomography predicts moderate or severe paravalvular regurgitation after transcatheter aortic valve replacement: a multicenter retrospective analysis. J Am Coll Cardiol 2012; 59: 1287-1294.

23. Unbehaun A, Pasic M, Dreyssé S, Dews T, Kuckucha M, Mladenow A, Ivanits-
kaja-Kühn E, Hetzer R, Buz S. Transapical aortic valve implantation: inci-
dence and predictors of paravalvular leakage and transvalvular regurgitation in a series of 358 patients. J Am Coll Cardiol 2012; 59: 211-221.

24. Petronio AS, Giannini C, De Carlo M. Mechanisms and prediction of aortic regurgitation after TAVI. EuroIntervention 2012; 8 Suppl Q: Q18-20.

25. Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, Anderson RH. 8. Leon MBM, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzel-

ley SG. Relationship of aortic annular eccentricity and paravalvular regurgitation post transcatheter aortic valve implantation: Influence on postprocedural paravalvular aortic regurgitation. J Thorac Cardiovasc Surg 2014; 147: 1847-1854.

26. Willmann JK, Weishaupt D, Lachat M, Kobza R, Roos JE, Seifert B, Lüscher TF. Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med 2010; 363: 1597-1607.

27. Patsalis PC, Koronza TF, Al-Rashid F, Plicht B, Riebisch M, Wemd D, Thiel-

mann M, Jakob H, Eggebrecht H, Heusch G, Erbel R, Kahler P. Incidence, outcome and correlates of residual paravalvular aortic regurgitation after transcatheter aortic valve implantation and importance of haemodynamic assessment. EuroIntervention 2013; 8: 1398-1406.

28. Masri A, Schoenhagen P, Svensson L, Kapadia SR, Griffin BP, Tuzcu EM, Desai MY. Dynamic characterization of aortic annulus geometry and morphology with multimodality imaging: Predictive value for aortic regurgitation after transcatheter aortic valve replacement. J Thorac Cardiovasc Surg 2010; 363: 1597-1607.

29. Sheriff MA, Abdel-Wahab M, Stöcker B, Geist V, Richardt D, Töig R, Richardt G. Anatomic and procedural predictors of paravalvular aortic regurgitation after implantation of the Medtronic CoreValve bioprosthesis. J Am Coll Cardiol 2010; 56: 1623-1629.

30. Messika-Zeitoun D, Aubry M-C, Detaint D, Bielak LF, Peyser PA, Sheedy PF, Cunningham D, MacCarthy PA. Device-dependent association between aortic regurgitation and outcome after TAVI. Heart 2014; 100: 356-362.

31. Holzhey DM, Mohr FW. Aortic valve calcium scoring is a predictor of signifi-
cant paravalvular aortic insufficiency in transapical-aortic valve implanta-
tion. Eurointervention 2013; 8: 1398-1406.

32. John D, Buellesfeld L, Yuecel S, Mueller R, Latsios G, Beucher H, Gerckens U, Holzhey DM, Mohr FW. Aortic valve calcium scoring is a predictor of signifi-
cant paravalvular aortic insufficiency in transapical-aortic valve implanta-
tion. JACC Cardiovasc Interv 2012; 5: 1247-1256.

33. DeGlopper RC, Roos JE, Pibarot P, Bernier M, Amat-Santos IJ, Mok M, Urena M, Rheault M, Dumesnil J, Côté M, Bilardo P, Dumont E. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv 2012; 5: 499-512.

34. Dvorakowski R, Wendler O, Halliday B, Ludman P, Debelder M, Ray S, Moat N, Kovac J, Spyt T, Trivedi U, Hildick-Smith D, Blackman D, Marlee D, Cunningham D, MacCarthy PA. Device-dependent association between paravalvar aortic regurgitation and outcome after TAVI. Heart 2014; 100: 1939-1945.
Risk factors for paravalvular leak after transcatheter aortic valve implantation

39. Roberts WC, Janning KG, Ko JM, Filardo G, Matter GJ. Frequency of congenitally bicuspid aortic valves in patients ≥ 80 years of age undergoing aortic valve replacement for aortic stenosis (with or without aortic regurgitation) and implications for transcatheter aortic valve implantation. Am J Cardiol 2012; 109: 1632-1636.

40. Himbert D, Pontneau F, Messika-Zeitoun D, Descoutures F, Détaint D, Cuffe C, Sondi M, Laiassy J-P, Alkhoder S, Brochet E, Jung B, Depoix J-P, Nataf P, Vahanian A. Feasibility and outcomes of transcatheter aortic valve implantation in high-risk patients with stenotic bicuspid aortic valves. Am J Cardiol 2012; 110: 877-883.

41. Kochman J, Huczek Z, Scisło P, Dabrowski M, Chmielak Z, Szymański P, Wilkowski A, Parma R, Ochala A, Chodór P, Reczuch KW, Kubiś P, Rymuza B, Koltowski L, Scibisz A, Wilinski R, Grube E, Opolski G. Comparison of one- and 12-month outcomes of transcatheter aortic valve replacement in patients with severely stenotic bicuspid versus tricuspid aortic valves (results from a multicenter registry). Am J Cardiol 2014; 114: 757-762.

42. Hayashida K, Bouvier E, Lefèvre T, Chevalier B, Hovasse T, Romano M, Garot P, Watanabe Y, Farge A, Donzeau-Gouge P, Cormier B, Morice MC. Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis. Circ Cardiovasc Interv 2013; 6: 284-291.

43. Abdel-Wahab M, Comberg T, Büttner HJ, El-Mawardy M, Chatani K, Gick M, Geist V, Richardt G, Neumann FJ. Aortic regurgitation after transcatheter aortic valve implantation with balloon- and self-expandable prostheses: a pooled analysis from a 2-center experience. JACC Cardiovasc Interv 2014; 7: 284-292.

44. Meredith AM, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Allocco DJ, Dawkins KD. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol 2014; 64: 1339-1348.

45. Schofer J, Colombo A, Klugmann S, Fajadet J, DeMarco F, Tchétché D, Maisano F, Brusch G, Latib A, Bijuklic K, Weissman N, Low R, Thomas M, Young C, Redwood S, Mullen M, Yap J, Grube E, Nickenig G, Sinning J-M, Hauptmann KE, Friedrich I, Lauterbach M, Schmoeckel M, Davidson C, Lefèvre T. Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve. J Am Coll Cardiol 2014; 63: 763-768.

46. Mylotte D, Dorfmeister M, Elhimi Y, Mazzetti D, Bleiziffer S, Wagner A, Noterdaeme T, Lange R, Piazza N. Errorneous measurement of the aortic annular diameter using 2-dimensional echocardiography resulting in inappropriate CoreValve size selection: a retrospective comparison with multislice computed tomography. JACC Cardiovasc Interv 2014; 7: 652-661.

47. Samim M, Stella PR, Agostoni P, Klun J, Ramjankhan F, Sieswerda G, Budde R, van der Linden M, Juthier F, Banfi C, Hurt C, Samim M, Hillaert M, van Herwerden L, Bertrand ME, Doevendans PAM, Van Belle E. A prospective “oversizing” strategy of the Edwards SAPIEN bioprosthesis: results and impact on aortic regurgitation. J Thorac Cardiovasc Surg 2013; 145: 398-405.

48. Poon KK, Crowhurst J, James C, Campbell D, Roper D, Chani J, Incani A, Clarke A, Tesar P, Aroney C, Raffel OC, Walters DL. Impact of optimising fluoroscopic implant angles on paravalvular regurgitation in transcatheter aortic valve replacements – utility of three-dimensional rotational angiography. EuroIntervention 2012; 8: 538-545.

49. Jilaihawi H, Chir D, Spyt T, Jelian M, Vasa-Nicotera M, Bence J, Loglans E, Kovac J. Prosthesis-patient mismatch after transcatheter aortic valve implantation with the Medtronic-CoreValve bioprosthesis. Eur Heart J 2010; 31: 857-864.

50. Wendler O, Walther T, Schroefel H, Lange R, Treede H, Fusani M, Rubino P, Thomas M. The SOURCE Registry: what is the learning curve in trans-apical aortic valve implantation? Eur J Cardiothorac Surg 2011; 39: 853-859.